Device profile of the XIENCE V and XIENCE Sierra stents for the treatment of coronary artery disease: an overview of safety and efficacy

References

• Gruntzig A, Schneider HJ. The percutaneous dilatation of chronic coronary stenoses–experiments and morphology. Schweiz Med Wochenschr. 1977;107(44):1588.
   PubMedGoogle Scholar
• Brophy JM, Belisle P, Joseph L. Evidence for use of coronary stents. A hierarchical bayesian meta-analysis. Ann Intern Med. 2003;138(10):7777–7786.
   Web of Science ®Google Scholar
• Serruys PW, de Jaegere P, Kiemeneij F, et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. N Engl J Med. 1994 Aug 25;331(8):489–495.
   PubMed Web of Science ®Google Scholar
• Fischman DL, Leon MB, Baim DS, et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent restenosis study investigators. N Engl J Med. 1994;331(8):496–501. .
   PubMed Web of Science ®Google Scholar
• Morice MC, Serruys PW, Sousa JE, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 2002;346(23):1773–1780. .
   PubMed Web of Science ®Google Scholar
• Valgimigli M, Percoco G, Malagutti P, et al. Tirofiban and sirolimus-eluting stent vs abciximab and bare-metal stent for acute myocardial infarction: a randomized trial. JAMA. 2005;293(17):2109–211715870414. .
   PubMed Web of Science ®Google Scholar
• Valgimigli M, Campo G, Percoco G, et al. Comparison of angioplasty with infusion of tirofiban or abciximab and with implantation of sirolimus-eluting or uncoated stents for acute myocardial infarction: the MULTISTRATEGY randomized trial. Jama. 2008 Apr 16;299(15):1788–1799.
   PubMed Web of Science ®Google Scholar
• Valgimigli M, Tebaldi M, Borghesi M, et al. Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (PROlonging dual antiplatelet treatment after grading stent-induced intimal hyperplasia studY). JACC Cardiovasc Interv. 2014;7:20–28..
   PubMedGoogle Scholar
• Joner M, Finn AV, Farb A, et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol. 2006 Jul 4;48(1):193–202.
   PubMed Web of Science ®Google Scholar
• Tada T, Byrne RA, Simunovic I, et al. Risk of stent thrombosis among bare-metal stents, first-generation drug-eluting stents, and second-generation drug-eluting stents: results from a registry of 18,334 patients. JACC Cardiovasc Interv. 2013;6(12):1267–1274.
   PubMed Web of Science ®Google Scholar
• Szott LM, Irvin CA, Trollsas M, et al. Blood compatibility assessment of polymers used in drug eluting stent coatings. Biointerphases. 2016;11(2):029806. .
   PubMed Web of Science ®Google Scholar
• Carter AJ, Brodeur A, Collingwood R, et al. Experimental efficacy of an everolimus eluting cobalt chromium stent. Catheter Cardiovasc Interv. 2006 Jul;68(1):97–103. .
   PubMed Web of Science ®Google Scholar
• Grube E, Buellesfeld L. Everolimus for stent-based intracoronary applications. Rev Cardiovasc Med. 2004;5 Suppl 2: S3–8. PMID: 15184828.
   PubMedGoogle Scholar
• Costa RA, Lansky AJ, Mintz GS, et al. Angiographic results of the first human experience with everolimus-eluting stents for the treatment of coronary lesions (the FUTURE I trial). Am J Cardiol. 2005 Jan 1;95(1):113–116.
   PubMed Web of Science ®Google Scholar
• Tsuchiya Y, Lansky AJ, Costa RA, et al. Effect of everolimus-eluting stents in different vessel sizes (from the pooled FUTURE I and II trials). Am J Cardiol. 2006 Aug 15;98(4):464–469. Epub 2006 Jun 19.
   PubMed Web of Science ®Google Scholar
• Serruys PW, Ong ATL, Piek JJ, et al. A randomized comparison of a durable polymer everolimus-eluting stent with a bare metal coronary stent: the SPIRIT first trial. Eurointervention. 2005;1(1):58–65.
   PubMedGoogle Scholar
• Tsuchida K, Piek JJ, Neumann FJ, et al. One-year results of a durable polymer everolimus-eluting stent in de novo coronary narrowings (The SPIRIT FIRST Trial). Eurointervention. 2005;1(3):266–272.
   PubMedGoogle Scholar
• Wiemer M, Serruys PW, Miquel-Hebert K, et al. Five-year long-term clinical follow-up of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo coronary artery lesions: the SPIRIT FIRST trial. Catheter Cardiovasc Interv. 2010 Jun 1;75(7):997–1003.
   PubMed Web of Science ®Google Scholar
• Serruys PW, Ruygrok P, Neuzner J, et al. A randomised comparison of an everolimus-eluting coronary stent with a paclitaxel-eluting coronary stent: the SPIRIT II trial. Eurointervention. 2006;2(3):286–294.
   PubMedGoogle Scholar
• Ruygrok PN, Desaga M, Van Den Branden F, et al. One year clinical follow-up of the XIENCE V everolimus-eluting stent system in the treatment of patients with de novo native coronary artery lesions: the SPIRIT II study. Eurointervention. 2007;3(3):315–320. .
   PubMedGoogle Scholar
• Claessen BE, Beijk MA, Legrand V, et al. Two-year clinical, angiographic, and intravascular ultrasound follow-up of the XIENCE V everolimus-eluting stent in the treatment of patients with de novo native coronary artery lesions: the SPIRIT II trial. Circ Cardiovasc Intervent. 2009;2(4):339–347.
   PubMed Web of Science ®Google Scholar
• Stone GW, Midei M, Newman W, et al. Comparison of an everolimus eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial. JAMA. 2008;299(16):1903–1913. .
   PubMed Web of Science ®Google Scholar
• Stone GW, Midei M, Newman W, et al., Randomized comparison of everolimus-eluting and paclitaxel-eluting stents two-year clinical follow-up from the clinical evaluation of the Xience V everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions (SPIRIT) III trial. Circulation. 119(5):680–686. 2009. .
   PubMed Web of Science ®Google Scholar
• Gada H, Kirtane AJ, Newman W, et al. 5-year results of a randomized comparison of XIENCE V everolimus-eluting and TAXUS paclitaxel-eluting stents: final results from the SPIRIT III trial (clinical evaluation of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions). JACC Cardiovasc Interv. 2013 Dec;6(12):1263–1266. .
   PubMed Web of Science ®Google Scholar
• Stone GW, Rizvi A, Newman W, et al. Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. N Engl J Med. 2010;362(18):1663–1674. .
   PubMed Web of Science ®Google Scholar
• Stone GW, Rizvi A, Sudhir K, et al. Randomized comparison of everolimus- and paclitaxel-eluting stents. 2-year follow-up from the SPIRIT (clinical evaluation of the XIENCE V everolimus eluting coronary stent system) IV trial. J Am Coll Cardiol. 2011 Jun 28;58(1):19–25. .
   PubMed Web of Science ®Google Scholar
• Cannon LA, Simon DI, Kereiakes D, et al. The XIENCE nano everolimus eluting coronary stent system for the treatment of small coronary arteries: the SPIRIT small vessel trial. Catheter Cardiovasc Interv. 2012 Oct 1;80(4):546–553. .
   PubMed Web of Science ®Google Scholar
• Grube E, Chevalier B, Smits P, et al. The SPIRIT V study: a clinical evaluation of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with de novo coronary artery lesions. JACC Cardiovasc Interv. 2011 Feb;4(2):168–175. .
   PubMed Web of Science ®Google Scholar
• Krucoff MW, Rutledge DR, Gruberg L, et al. A new era of prospective real-world safety evaluation primary report of XIENCE V USA (XIENCE V everolimus eluting coronary stent system condition-of-approval postmarket study). JACC Cardiovasc Interv. 2011;4(12):1298–1309. .
   PubMed Web of Science ®Google Scholar
• Seth A, Patel TM, Stuteville M, et al. Three-year data from the XIENCE V INDIA study: safety and efficacy of XIENCE V in 1000 real world Indian patients. Indian Heart J. 2014 May-Jun;66(3):302–308. .
   PubMedGoogle Scholar
• Palmerini T, Biondi-Zoccai G, Della Riva D, et al. Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. Lancet. 2012;379(9824):1393–1402. .
   PubMed Web of Science ®Google Scholar
• Valgimigli M, Sabaté M, Kaiser C, et al. Effects of cobalt-chromium everolimus eluting stents or bare metal stent on fatal and non-fatal cardiovascular events: patient level meta-analysis. BMJ. 2014 Nov;4(349):g6427. .
   Google Scholar
• Piccolo R, Bonaa KH, Efthimiou O, et al. Drug-eluting or bare-metal stents for percutaneous coronary intervention: a systematic review and individual patient data meta-analysis of randomised clinical trials. Lancet. 2019 Jun 22;393(10190):2503–2510. .
   PubMed Web of Science ®Google Scholar
• Kandzari DE, Mauri L, Koolen JJ, et al., Ultrathin, bioresorbable polymer sirolimus-eluting stents versus thin, durable polymer everolimus-eluting stents in patients undergoing coronary revascularisation (BIOFLOW V): a randomised trial. Lancet. 390(10105):1843–1852. 2017. .
   PubMed Web of Science ®Google Scholar
• Pilgrim T, Heg D, Roffi M, et al., Ultrathin strut biodegradable polymer sirolimus‐eluting stent versus durable polymer everolimus‐eluting stent for percutaneous coronary revascularisation (BIOSCIENCE): a randomised, single‐blind, non‐inferiority trial. Lancet. 384(9960):2111–2122. 2014. .
   PubMed Web of Science ®Google Scholar
• Pilgrim T, Piccolo R, Heg DH, et al. Ultrathin-strut, biodegradable-polymer, sirolimus-eluting stents versus thin-strut, durable-polymer, everolimus-eluting stents for percutaneous coronary revascularisation: 5-year outcomes of the BIOSCIENCE randomised trial. Lancet. 2018 Sep 1;392(10149):737–746.
   PubMed Web of Science ®Google Scholar
• Iglesias JF, Muller O, Heg D, et al. Biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents in patients with ST-segment elevation myocardial infarction (BIOSTEMI): a single-blind, prospective, randomised superiority trial. Lancet. 2019 Oct 5;394(10205):1243–1253. .
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov [Internet]. NCT03967158, Evaluation of effectiveness and safety of XIENCE Sierra in routine clinical practice (IRIS Sierra). National Library of Medicine (US).
   Google Scholar
• ClinicalTrials.gov [Internet]. NCT02042300, XIENCE Xpedition/Alpine/Sierra in routine clinical practice (IRIS XPEDITION).
   Google Scholar
• ClinicalTrials.gov [Internet]. NCT03567733, Prospective registry of patients over 75 years old treated with Xience Sierra Stents. Sierra 75 study (SIERRA 75). National Library of Medicine (US)
   Google Scholar
• ClinicalTrials.gov [Internet]. NCT03218787, XIENCE 90: A safety evaluation of 3-month DAPT after XIENCE implantation for HBR patients. National Library of Medicine (US)
   Google Scholar
• ClinicalTrials.gov [Internet]. NCT03815175, XIENCE 28 USA study. National Library of Medicine (US).
   Google Scholar